Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Recent research on allogeneic mesenchymal stem/stromal cell (MSC) therapy spans multiple therapeutic areas, with emerging evidence from both preclinical studies and clinical trials.
Clinical Trial Development
The HULC-2 study represents a significant advancement in neonatal care - a phase 2 multicentre, double-blind randomized controlled trial examining mesenchymal stromal cells for extreme preterm infants at risk of bronchopulmonary dysplasia in Canada. This builds upon earlier phase 1 work, including a completed study (NCT03635450) that tested human cord tissue-derived MSCs in newborns with moderate to severe hypoxic-ischemic encephalopathy.
Graft-Versus-Host Disease Applications
Multiple studies focus on MSCs for graft-versus-host disease (GVHD). One 2026 study examined Wharton's jelly-derived MSCs from human umbilical cord for treating steroid-resistant GVHD, developing a validated immunopotency assay to predict clinical response. Another investigated the interaction between vedolizumab and umbilical cord-derived MSCs in acute GVHD, exploring combination therapeutic approaches.
Autoimmune and Inflammatory Conditions
Research continues into MSC therapy for systemic lupus erythematosus, with a 2026 review examining mechanisms and clinical translation prospects. A phase 2 trial (NCT01539902) specifically targets lupus nephritis using human umbilical cord-derived MSCs. Additional studies explore MSC applications in ulcerative colitis (NCT03609905, phase 1-2) and COVID-19-associated acute kidney injury requiring renal replacement therapy (NCT04445220).
Immunological Considerations
A 2026 equine study revealed that MHC compatibility has greater influence on humoral immune responses to MSCs than inflammatory priming or chondrogenic differentiation, providing important insights for allogeneic therapy optimization.
Other Applications
Completed trials include MSC therapy for cerebellar ataxia (NCT01649687, phase 1-2), while observational studies examine MSC treatment effects on retinopathy of prematurity in patients with bronchopulmonary dysplasia.
The evidence base remains mixed in quality, with many trials of unknown status and varying study designs. Most clinical trials are early-phase (phase 1-2), indicating the field is still establishing safety profiles and optimal dosing before larger efficacy studies.
This information is for educational purposes only and does not constitute medical advice. Patients should consult healthcare providers for treatment decisions.